Ravulizumab

Ravulizumab Overview

Ravulizumab (INN;[1] trade name Ultomiris) is a humanized monoclonal antibody designed for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. This drug was developed by Alexion Pharmaceuticals, Inc.[2] It was approved by the US Food and Drug Administration in December 2018.[3] In April 2019, the European CHMP of EMA recommended the granting of a conditional marketing authorisation for ravulizumab. ...

Read more Ravulizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ravulizumab

Recent Ravulizumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Other drugs which contain Ravulizumab or a similar ingredient: (1 result)

• ULTOMIRIS Ravulizumab-cwvz